The safety of long-acting β₂-agonists in the treatment of stable chronic obstructive pulmonary disease

References

• Centers for Disease Control and PreventionDeaths: preliminary data for 2009National Vital Statistics Reports2011594 Available from: http://www.cdc.gov/nchs/data/nvsr/nvsr59/nvsr59_04.pdfAccessed September 28, 2012
   Google Scholar
• World Health Organization (WHO)Chronic respiratory diseases: chronic obstructive pulmonary disease [web page on the Internet]GenevaWHO Chronic Diseases and Health Promotion Department nd. Available from: http://www.who.int/respiratory/copd/en/Accessed December 3, 2012
   Google Scholar
• O’DonnellDEHyperinfation, dyspnea, and exercise intolerance in chronic obstructive pulmonary diseaseProc Am Thorac Soc20063218018416565429
   PubMedGoogle Scholar
• O’DonnellDEDynamic lung hyperinflation and its clinical implication in COPDRev Mal Respir2008251013051318 French19107020
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease (GOLD)global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary DiseaseRev ed. GOLD; 2011 Available from: http://www.goldcopd.org/uploads/users/fles/GOLD_Report_2011_Feb21.pdfAccessed June 14, 2012
   Google Scholar
• NorrisSLYenPYDanaTLCareBRBurdaBUDrug Class Review: Beta₂-agonistsPortland, OROregon Health and Science University2006 Available from: http://www.ncbi.nlm.nih.gov/books/NBK10429/Accessed September 28, 2012
   Google Scholar
• CalverleyPMAndersonJACelliBSalmeterol and fluticasone propionate and survival in chronic obstructive pulmonary diseaseN Engl J Med2007356877578917314337
   PubMed Web of Science ®Google Scholar
• CalverleyPMNew options for bronchodilator treatment in COPDThorax201065646846920522838
   PubMed Web of Science ®Google Scholar
• HananiaNASharafkhanehACelliBAcute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trialRespir Res201112621219660
   PubMed Web of Science ®Google Scholar
• TashkinD PCelliBSennSUPLIFT Study InvestigatorsA 4-year trial of tiotropium in chronic obstructive pulmonary diseaseN Engl J Med2008359151543155418836213
   PubMed Web of Science ®Google Scholar
• O’DonnellDEWebbKAThe major limitation to exercise performance in COPD is dynamic hyperinflationJ Appl Physiol20081052753755 discussion75575718678624
   PubMed Web of Science ®Google Scholar
• BrienzaNSAmor-CarroORamos-BarbónDAn update on the use of indacaterol in patients with COPDTher Adv Respir Dis201151294021059700
   PubMedGoogle Scholar
• RodrigoGJNanniniLJRodríguez-RoisinRSafety of long-acting beta-agonists in stable COPD: a systematic reviewChest200813351079108718460518
   PubMed Web of Science ®Google Scholar
• TashkinD PFabbriLMLong-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agentsRespir Res20101114921034447
   PubMed Web of Science ®Google Scholar
• Allen and Hanburys LtdSerevent Accuhaler [summary of product characteristics]. electronic Medicines Compendium (eMC)updated 5172012 Available from: http://www.medicines.org.uk/EMC/medicine/91/SPC/Serevent+Accuhaler/Accessed September 11, 2012
   Google Scholar
• Allen and Hanburys LtdSerevent Diskus [summary of product characteristics]. eMCupdated 5172012 Available from: http://www.medicines.org.uk/EMC/medicine/92/SPC/Serevent+Diskhaler/Accessed September 11, 2012
   Google Scholar
• Allen and Hanburys LtdSerevent Evohaler [summary of product characteristics]. eMCupdated 5242012 Available from: http://www.medicines.org.uk/EMC/medicine/17201/SPC/Serevent+Evohaler/Accessed September 11, 2012
   Google Scholar
• Novartis Pharmaceuticals UK LtdForadil [summary of product characteristics] Available from: http://www.medicines.org.uk/EMC/medicine/1286/SPC/Foradil/eMC; updated10122012Accessed September 11, 2012
   Google Scholar
• Novartis Pharmaceuticals UK LtdOnbrez Breezhaler 150 and 300 microgram inhalation powder, hard capsules [summary of product characteristics]. eMCupdated 8142012 Available from: http://www.medicines.org.uk/EMC/searchresults.aspx?term=onbrezAccessed September 11, 2012
   Google Scholar
• PriceDBYawnB PJonesRCImproving the differential diagnosis of chronic obstructive pulmonary disease in primary careMayo Clin Proc201085121122112921123639
   PubMed Web of Science ®Google Scholar
• BlanchetteCMBerrySRLaneSJAdvances in chronic obstructive pulmonary disease among older adultsCurr Opin Pulm Med2011172848921178625
   PubMed Web of Science ®Google Scholar
• LangePScharlingHUlrikCSVestboJInhaled corticosteroids and decline of lung function in community residents with asthmaThorax200661210010416443705
   PubMed Web of Science ®Google Scholar
• Global Initiative for Asthma (GINA)Global Strategy for Asthma Management and PreventionNIH Publication No 02-3659Bethesda, MDNational Institutes of Health1995 [updated 2005]. Available from: http://www.ginasthma.org/pdf/archived/GINAWorkshop05Clean.pdfAccessed June 14, 2012
   Google Scholar
• NelsonHSWeissSTBleeckerERYanceyS WDorinskyPMSMART Study GroupThe Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterolChest20061291152616424409
   PubMed Web of Science ®Google Scholar
• SearsMROttossonARadnerFSuissaSLong-acting beta-agonists: a review of formoterol safety data from asthma clinical trialsEur Respir J2009331213218768573
   PubMed Web of Science ®Google Scholar
• BeasleyRMartinezFDHackshawASafety of long-acting beta-agonists: urgent need to clear the air remainsEur Respir J20093313519118222
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration (FDA)FDA Drug Safety Communication: Drug labels now contain updated recommendations on the appropriate use of long-acting inhaled asthma medications called Long-Acting Beta-Agonists (LABAs) [web page on the Internet]Silver Spring, MDFDAupdated 4152011 Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm213836.htmAccessed September 28, 2012
   Google Scholar
• JenkinsCRCelliBAndersonJASeasonality and determinants of moderate and severe COPD exacerbations in the TORCH studyEur Respir J2012391384521737561
   PubMed Web of Science ®Google Scholar
• FearyJRRodriguesLCSmithCJHubbardRBGibsonJEPrevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary careThorax2010651195696220871122
   PubMed Web of Science ®Google Scholar
• Dal NegroRWPomariCTognellaSMichelettoCSalmeterol and fluticasone 50 microg/250 microg bid in combination provides a better long-term control than salmeterol 50 microg bid alone and placebo in COPD patients already treated with theophyllinePulm Pharmacol Ther200316424124612850128
   PubMed Web of Science ®Google Scholar
• CalverleyPMBoonsawatWCsekeZZhongNPetersonSOlssonHMaintenance therapy with budesonide and formoterol in chronic obstructive pulmonary diseaseEur Respir J200322691291914680078
   PubMed Web of Science ®Google Scholar
• KliberALyndLDSinDDThe effects of long-acting bronchodilators on total mortality in patients with stable chronic obstructive pulmonary diseaseRespir Res2010115620459831
   PubMed Web of Science ®Google Scholar
• DonohueJFSinghDKornmannOLawrenceDLassenCKramerBSafety of indacaterol in the treatment of patients with COPDInt J Chron Obstruct Pulmon Dis2011647749222003293
   PubMed Web of Science ®Google Scholar
• LeeTAPickardASAuDHBartleBWeissKBRisk for death associated with medications for recently diagnosed chronic obstructive pulmonary diseaseAnn Intern Med2008149638039018794557
   PubMed Web of Science ®Google Scholar
• MapelDWNelsonLSLydickESorianoJYoodMUDavisKJSurvival among COPD patients using fluticasone/salmeterol in combination versus other inhaled steroids and bronchodilators aloneCOPD20074212713417530506
   PubMedGoogle Scholar
• WangJNieBXiongWXuYEffect of long-acting beta-agonists on the frequency of COPD exacerbations: a meta-analysisJ Clin Pharm Ther201237220421121740451
   PubMed Web of Science ®Google Scholar
• CalverleyPMAndersonJACelliBTORCH InvestigatorsCardiovascular events in patients with COPD: TORCH study resultsThorax201065871972520685748
   PubMed Web of Science ®Google Scholar
• WorthHChungKFFelserJMHuHRueeggPCardio- and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPDRespir Med2011105457157921227674
   PubMed Web of Science ®Google Scholar
• DahlRChungKFBuhlRINVOLVE (INdacaterol: Value in COPD: Longer Term Validation of Efficacy and Safety) Study Investigators Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPDThorax201065647347920522841
   PubMed Web of Science ®Google Scholar
• KornmannODahlRCentanniSINLIGHT-2 (Indacaterol Efficacy Evaluation Using 150-μg Doses with COPD Patients) study investigators Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparisonEur Respir J201137227327920693243
   PubMed Web of Science ®Google Scholar
• DonohueJFFogartyCLötvallJINHANCE Study InvestigatorsOnce-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropiumAm J Respir Crit Care Med2010182215516220463178
   PubMed Web of Science ®Google Scholar
• ChapmanKRRennardSIDograAOwenRLassenCKramerBINDORSE Study InvestigatorsLong-term safety and efficacy of indacaterol, a long-acting β2-agonist, in subjects with COPD: a randomized, placebo-controlled studyChest20111401687521349928
   PubMed Web of Science ®Google Scholar
• ManninoDMDohertyDESonia BuistAGlobal Initiative on Obstructive Lung Disease (GOLD) classification of lung disease and mortality: findings from the Atherosclerosis Risk in Communities (ARIC) studyRespir Med2006100111512215893923
   PubMed Web of Science ®Google Scholar
• InsulanderPJuhlin-DannfeltAFreyschussUVallinHElectrophysiologic effects of salbutamol, a beta2-selective agonistJ Cardiovasc Electrophysiol200415331632215030423
   PubMed Web of Science ®Google Scholar
• SalpeterSROrmistonTMSalpeterEECardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysisChest200412562309232115189956
   PubMed Web of Science ®Google Scholar
• CazzolaMMateraMGDonnerC FInhaled beta2-adrenoceptor agonists: cardiovascular safety in patients with obstructive lung diseaseDrugs200565121595161016060696
   PubMed Web of Science ®Google Scholar
• WilcheskyMErnstPBrophyJMPlattRWSuissaSBronchodilator use and the risk of arrhythmia in COPD: part 2: reassessment in the larger Quebec cohortChest2012142230531122871756
   PubMed Web of Science ®Google Scholar
• ErnstPGonzalezAVBrassardPSuissaSInhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumoniaAm J Respir Crit Care Med2007176216216617400730
   PubMed Web of Science ®Google Scholar
• GarchaDSThurstonSJPatelARChanges in prevalence and load of airway bacteria using quantitative PCR in stable and exacerbated COPDThorax201267121075108022863758
   PubMed Web of Science ®Google Scholar
• HurstJRVestboJAnzueto A, et al; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Susceptibility to exacerbation in chronic obstructive pulmonary diseaseN Engl J Med2010363121128113820843247
   PubMed Web of Science ®Google Scholar
• CazzolaMMacNeeWMartinezFJet al; American Thoracic Society; European Respiratory Society Task Force on outcomes ofCOPDOutcomes for COPD pharmacological trials: from lung function to biomarkersEur Respir J200831241646918238951
   PubMed Web of Science ®Google Scholar
• LambertRKWiggsBRKuwanoKHoggJCParePDFunctional significance of increased airway smooth muscle in asthma and COPDJ Appl Physiol1993746277127818365980
   PubMed Web of Science ®Google Scholar
• McivorRAPizzichiniETurnerMOHussackPHargreaveFESearsMRPotential masking effects of salmeterol on airway inflammation in asthmaAm J Respir Crit Care Med199815839249309731027
   PubMed Web of Science ®Google Scholar
• LipworthBJAntagonism of long-acting beta2-adrenoceptor agonismBr J Clin Pharmacol200254323124512236842
   PubMed Web of Science ®Google Scholar
• O’DonnellDEIs sustained pharmacologic lung volume reduction now possible in COPD?Chest2006129350150316537841
   PubMed Web of Science ®Google Scholar
• McGrawDWAlmoosaKFPaulRJKobilkaBKLiggettSBAntithetic regulation by beta-adrenergic receptors of Gq receptor signaling via phospholipase C underlies the airway beta-agonist paradoxJ Clin Invest2003112461962612925702
   PubMed Web of Science ®Google Scholar
• NguyenL PLinRParraSBeta2-adrenoceptor signaling is required for the development of an asthma phenotype in a murine modelProc Natl Acad Sci U S A200910672435244019171883
   PubMed Web of Science ®Google Scholar
• HananiaNASinghSEl-WaliRThe safety and effects of the beta-blocker, nadolol, in mild asthma: an open-label pilot studyPulm Pharmacol Ther200821113414117703976
   PubMed Web of Science ®Google Scholar
• LipworthBJWilliamsonPABeta blockers for asthma: a double-edged swordLancet2009373965810410519135598
   PubMed Web of Science ®Google Scholar
• GibsonPGMcDonaldVMMarksGBAsthma in older adultsLancet2010376974380381320816547
   PubMed Web of Science ®Google Scholar
• WedzichaJACalverleyPMSeemungalTAHaganGAnsariZStockleyRAINSPIRE InvestigatorsThe prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromideAm J Respir Crit Care Med20081771192617916806
   PubMed Web of Science ®Google Scholar
• VogelmeierCHedererBGlaabTPOET-COPD InvestigatorsTiotropium versus salmeterol for the prevention of exacerbations of COPDN Engl J Med2011364121093110321428765
   PubMed Web of Science ®Google Scholar
• WedzichaJDecramerMSeemungalTThe role of bronchodilator treatment in the prevention of exacerbations of COPDEur Respir JEpub 7262012
   Google Scholar
• TiengoAFadiniG PAvogaroAThe metabolic syndrome, diabetes and lung dysfunctionDiabetes Metab200834544745418829364
   PubMed Web of Science ®Google Scholar
• RabeK FTreating COPD – the TORCH trial, P values, and the DodoN Engl J Med2007356885185417314345
   PubMed Web of Science ®Google Scholar
• La VecchiaCFabbriLMPrevention of death in COPDN Engl J Med2007356212211221217526088
   PubMed Web of Science ®Google Scholar
• SuissaSErnstPVandemheenKLAaronSDMethodological issues in therapeutic trials of COPDEur Respir J200831592793318216056
   PubMed Web of Science ®Google Scholar
• Rossi A, Kristufek P, Levine BE, et al; Formoterol in Chronic Obstructive Pulmonary Disease (FICOPD) II Study Group. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPDChest200212141058106911948033
   PubMed Web of Science ®Google Scholar
• SzafranskiWCukierARamirezAEfficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary diseaseEur Respir J2003211748112570112
   PubMed Web of Science ®Google Scholar
• CampbellMElirazAJohanssonGFormoterol for maintenance and as-needed treatment of chronic obstructive pulmonary diseaseRespir Med200599121511152016199148
   PubMed Web of Science ®Google Scholar
• TashkinD PRennardSIMartinPEfficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trialDrugs200868141975200018778120
   PubMed Web of Science ®Google Scholar
• VogelmeierCKardosPHarariSGansSJStengleinSThirlwellJFormoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month studyRespir Med2008102111511152018804362
   PubMed Web of Science ®Google Scholar
• RennardSITashkinD PMcElhattanJEfficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trialDrugs200969554956519368417
   PubMed Web of Science ®Google Scholar
• DohertyDETashkinD PKerwinEEffects of mometasone furoate/formoterol fumarate fixed-dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52-week Phase III trial in subjects with moderate-to-very severe COPDInt J Chron Obstruct Pulmon Dis20127577122334769
   PubMed Web of Science ®Google Scholar
• TashkinD PDohertyDEKerwinEEfficacy and safety of a fixed-dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52-week Phase III trialInt J Chron Obstruct Pulmon Dis20127435522334768
   PubMed Web of Science ®Google Scholar
• MahlerDAWirePHorstmanDEffectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary diseaseAm J Respir Crit Care Med200216681084109112379552
   PubMed Web of Science ®Google Scholar
• ChapmanKRArvidssonPChuchalinAGInternational study groupThe addition of salmeterol 50 microg bid to anticholinergic treatment in patients with COPD: a randomized, placebo controlled trial. Chronic obstructive pulmonary diseaseCan Respir J20029317818512068339
   PubMedGoogle Scholar
• CalverleyPPauwelsRVestboJTRial of Inhaled STeroids ANd long-acting beta2 agonists study groupCombined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trialLancet2003361935644945612583942
   PubMed Web of Science ®Google Scholar
• BrusascoVHodderRMiravitllesMKorduckiLTowseLKestenSHealth outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPDThorax200358539940412728159
   PubMed Web of Science ®Google Scholar
• HananiaNADarkenPHorstmanDThe efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPDChest2003124383484312970006
   PubMed Web of Science ®Google Scholar
• StockleyRAChopraNRiceLAddition of salmeterol to existing treatment in patients with COPD: a 12 month studyThorax200661212212816443706
   PubMed Web of Science ®Google Scholar
• FDAFDA Pulmonary-allergy Drugs Advisory Committee Meeting September 6, 2002: Spiriva® (tiotropium bromide) Inhalation PowderNDA 21-395Silver Spring, MDFDA2002 Available from: http://www.fda.gov/ohrms/dockets/ac/02/briefng/3890B1_01_Boehringer%20Ingelheim.pdfAccessed April 30, 2012
   Google Scholar